{"doi":"10.1128/aac.01299-20","title":"Filociclovir Is a Potent<i>In Vitro</i>and<i>In Vivo</i>Inhibitor of Human Adenoviruses","abstract":") of 100 to 150 μM in human foreskin fibroblasts (HFFs). We also show that the prophylactic oral administration of FCV (10 mg/kg of body weight) 1 day prior to virus challenge and then daily for 14 days to immunosuppressed Syrian hamsters infected intravenously with HAdV6 was sufficient to prevent morbidity and mortality. FCV also mitigated tissue damage and inhibited virus replication in the liver. The 10-mg/kg dose had similar effects even when the treatment was started on day 4 after virus challenge. Furthermore, FCV administered at the same dose after intranasal challenge with HAdV6 partially mitigated body weight loss but significantly reduced pathology and virus replication in the lung. These findings suggest that FCV could potentially be developed as a pan-adenoviral inhibitor.","journal":"Antimicrobial Agents and Chemotherapy","year":2020,"id":78149,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":18,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9558,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":408058,"name":"Islam T. M. Hussein","orcid":null,"position":1,"is_corresponding":false},{"id":406803,"name":"Ann E. Tollefson","orcid":"0000-0001-5010-3241","position":2,"is_corresponding":false},{"id":408059,"name":"Baoling Ying","orcid":null,"position":3,"is_corresponding":false},{"id":406804,"name":"Jacqueline F. Spencer","orcid":"0000-0002-9568-4374","position":4,"is_corresponding":false},{"id":408060,"name":"Jessica Eagar","orcid":null,"position":5,"is_corresponding":false},{"id":335180,"name":"Scott H. James","orcid":"0009-0007-6817-4217","position":6,"is_corresponding":false},{"id":406805,"name":"Mark N. Prichard","orcid":"0000-0002-2720-6661","position":7,"is_corresponding":false},{"id":408061,"name":"William S.M. Wold","orcid":null,"position":8,"is_corresponding":false},{"id":391953,"name":"Terry L. Bowlin","orcid":"0000-0002-9184-5791","position":9,"is_corresponding":false},{"id":406802,"name":"Károly Tóth","orcid":"0000-0001-6624-9683","position":0,"is_corresponding":true}],"reference_count":60,"raw_metadata":null,"created_at":"2026-07-18T21:49:40.769098Z","pmid":"32816736","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}